Olverembatinib is a targeted therapy indicated for the treatment of specific types of leukemia. It is primarily prescribed for patients with chronic myeloid leukemia (CML), especially those who are refractory to or intolerant of prior therapies. The following instructions must be strictly followed before and during medication use:
I. Indications and Medication Principles
Patient Population
Suitable for patients diagnosed with chronic myeloid leukemia (CML) harboring the T315I mutation, or those who have failed treatment with other tyrosine kinase inhibitors.
Medication Principles
Administration must be under the supervision of a physician. Dosage adjustment or discontinuation is not permitted without medical guidance.
II. Dosage and Administration
Dosage Specifications
The recommended dosage is once-daily oral administration. The specific dose should be adjusted based on the patient’s body weight, disease status and adverse reactions, and must strictly comply with the physician’s instructions.
Administration Instructions
It is advisable to take the medication at a fixed time, either on an empty stomach or with meals. Avoid concurrent administration with high-fat meals.
III. Common Adverse Reactions and Management
Hematological Reactions
Adverse events such as anemia and thrombocytopenia may occur. Regular monitoring of complete blood count (CBC) is required.
Non-hematological Reactions
Include rash, edema, arthralgia, etc. Mild symptoms can be managed symptomatically; prompt medical attention should be sought for severe manifestations.
Cardiotoxicity
Though rare, the drug may induce QT interval prolongation. Regular electrocardiogram (ECG) monitoring is necessary during the treatment course.
IV. Contraindications and Precautions
Contraindicated Populations
Patients hypersensitive to any component of the drug, and pregnant women (due to potential teratogenic risks).
Populations Requiring Caution
Patients with hepatic or renal insufficiency, or those with underlying cardiac diseases, must be closely monitored during treatment.
V. Drug Interactions
Avoid Concomitant Use
Potent CYP3A inhibitors (e.g., clarithromycin) or inducers (e.g., rifampicin) are not recommended for co-administration, as they may alter drug efficacy or increase toxicity risk.
Other Medications
Caution is required when combining with anticoagulants or antiarrhythmic drugs. Patients must inform their physicians of their full medication history in a timely manner.
VI. Precautions
Monitoring Requirements
During the initial treatment phase, complete blood count should be reviewed every 1–2 weeks. Treatment efficacy should be evaluated every 3 months (e.g., via bone marrow examination and genetic testing).
Storage Conditions
Store below 30℃ in a light-protected place. Keep out of reach of children.
VII. Medical Consultation Guidelines
Prompt Communication
In case of fever, dyspnea, chest pain or severe rash, discontinue the drug immediately and seek medical attention.
Long-term Management
Regular follow-up visits are essential to assess treatment efficacy and safety. Any adjustment to the treatment regimen must be determined by a specialist physician.
Note: Olverembatinib is a prescription-only medication and must be used strictly in accordance with physician instructions. It should not replace other standard treatments. Maintain close communication with your physician throughout the treatment period to ensure medication safety.
